Investments, Funding & Disinvestment

Liminatus went public in 2022 through a SPAC merger and initially highlighted several immune-modulating therapies originating from research collaborations in the United States and South Korea.

Once completed, the acquisition will integrate SPR’s technology into Medtronic’s broader pain management strategy, allowing the company to offer additional options for patients and clinicians seeking alternatives to drug-based therapies.

Fujifilm Cellular Dynamics will use the expanded site to produce its iCell product portfolio, which plays a key role in new approach methods (NAMs) used in modern drug discovery and toxicity testing.

Health authorities have continued to emphasise coordinated cross-border surveillance, especially given the movement of populations between affected regions in DRC and Uganda.

The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.

CVC, already the majority shareholder with a 46.8% stake, has positioned the move as a long-term strategic consolidation rather than a short-term financial transaction.

The report estimates that improved interventions could help over 1.2 million adults transition out of obesity by 2031.

Since December 2025, CBC Group, together with the company’s directors have cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).

Kenya aligned its position with the African regional statement presented by Zimbabwe on behalf of the WHO African Region, reinforcing a continent-wide call for equity at the heart of global health governance and emergency response.

Since the partnership began, Gilead has supplied more than 1.1 million vials of AmBisome and contributed over US$18 million in funding.